Literature DB >> 20740147

Meigs' Syndrome with Elevated Serum CA125: Case Report and Review of the Literature.

Mongkol Benjapibal1, Suthi Sangkarat, Somsak Laiwejpithaya, Boonlert Viriyapak, Pattama Chaopotong, Atthapon Jaishuen.   

Abstract

An elevated serum CA125 level in association with a pelvic mass, pleural effusion, and massive ascites usually signifies a dismal prognosis in a postmenopausal woman. However, surgery and histopathological examination are required for the correct diagnosis and treatment, since an elevated CA125 level can be falsely positive for ovarian malignancy. We present a case of Meigs' syndrome due to right ovarian fibroma with elevated CA125 level in a postmenopausal woman.

Entities:  

Year:  2009        PMID: 20740147      PMCID: PMC2918831          DOI: 10.1159/000210441

Source DB:  PubMed          Journal:  Case Rep Oncol        ISSN: 1662-6575


Introduction

The importance of ovarian cancer stems not from the fact that it is the sixth most common cancer in women worldwide, but from the fact that it is the most lethal gynecologic malignancy in Western Europe and North America, killing more women than uterine and cervical cancer combined. It is predominantly a disease of postmenopausal women, with a median age at diagnosis of 60 years [1]. Elevated serum CA125 levels in postmenopausal women with solid adnexal masses, ascites, and pleural effusion are highly suggestive for malignant ovarian tumor. However, surgery and histological confirmation of the preoperative diagnosis are mandatory, since a minority of patients with these findings have a benign condition, commonly known as Meigs’ syndrome. This condition disappears after removal of the pelvic tumor. We report a case of Meigs’ syndrome caused by right ovarian fibroma with elevated serum CA125 level in a postmenopausal woman.

Case Report

A 56-year-old Thai woman was admitted to another hospital because of progressive dyspnea, abdominal distention and weight loss for 8 months. Her obstetric history included 3 uncomplicated deliveries. She had a history of diabetes mellitus since the age of 46 and her menopause occurred at the age of 52 years. The patient did not complain of any pain or changes in micturition or bowel habits. Her mother had died from endometrial cancer and her sister had a history of breast cancer. Marked right pleural effusion, ascites, and a large abdominal mass were found. Thoracocentesis was done to relieve her dyspnea. The cytology revealed atypical cells suggestive of malignancy. The patient was then referred to our hospital. On physical examination, there was dullness to percussion with decreased breath sounds in the half of the right lung field. Abdominal examination revealed shifting dullness and a palpable mass reaching to the umbilicus. On pelvic examination, a hard nodular 14 × 12 cm mass was palpated; a separate uterus could not be discerned. Ultrasonography of the abdomen and pelvis confirmed a moderate amount of ascites, the uterus appeared normal and a right adnexal solid mass of 14 × 12 cm was found. A chest X-ray revealed the presence of a massive right-sided and a minimal left-sided pleural effusion. Repeat thoracocentesis of right lung yielded 1,500 ml of fluid containing reactive mesothelial cells without evidence of malignancy noted on cytology review. Gram stain and acid fast stains also were reported as negative. Pleural biopsy was done and revealed non-specific chronic pleurisy. Blood chemistry was within normal limits except for a serum CA125 level of 1,064 U/ml (normal range 0-35 U/ml). Due to clinical suspicion of malignant ovarian tumor, the patient was submitted to exploratory laparotomy which revealed 2,500 ml of serous ascites. After aspiration of the ascitic fluid, a 13 × 10 × 10-cm lobulated right adnexal solid mass without excrescences was found (fig. 1). The uterus and left adnexa appeared normal. Frozen section of the right adnexal mass was read as benign ovarian fibroma. There was no palpable pelvic or periaortic adenopathy; the liver, diaphragm, bowel, and omentum were grossly free of disease. The patient subsequently underwent a total abdominal hysterectomy with bilateral salpingo-oophorectomy. Pathological examination of the specimen showed a benign fibroma of the right ovary.
Fig. 1

Right ovarian fibroma measuring 13 × 10 × 10 cm and weighing 690 g.

The postoperative period was uneventful and the patient was discharged on the seventh postoperative day. The serum CA125 level on the sixth postoperative day was 22 U/ml. Six weeks postoperatively, she was followed on an outpatient basis without further complaints. The pleural effusion was resolved completely on repeat chest X-ray. The patient was asymptomatic with a normal serum CA125 level 6 months after the operation.

Discussion

In 1934, Salmon described the association of pleural effusion with benign pelvic tumors. It was not until the report by Meigs and Cass in 1937 that widespread attention of the medical profession was drawn to the significance of pleural effusion and ascites in benign ovarian fibroma [2]. Meigs’ syndrome is defined as the triad of benign ovarian tumor with ascites and pleural effusion that resolves after resection of the tumor. Although Meigs’ syndrome mimics a malignant condition, it is a benign disease and has a very good prognosis if properly managed. Life expectancy after surgical removal of the tumor mirrors that of the general population. Ovarian fibroma is found in 2-5% of surgically removed ovarian tumors [3], and Meigs’ syndrome is observed in about 1% [4]. Ascites is present in 10-15% of those with ovarian fibroma and pleural effusion in 1%, especially with large lesion [5, 6]. The pathophysiology of ascites in Meigs’ syndrome is subject to debate and remains unclear. Meigs suggested that irritation of the peritoneal surfaces by a hard, solid ovarian tumor could stimulate the production of peritoneal fluid [7]. Other proposed mechanisms are direct pressure on surrounding lymphatics or vessels, hormonal stimulation, or release of mediators from the tumor, leading to increased capillary permeability [5, 8, 9]. The etiology of pleural effusion is unclear. It is thought that the occurrence of pleural effusion is secondary to the passage of ascitic fluid to the pleural space through the diaphragm or diaphragmatic lymph vessels which are more common on the right side [10]. The size of the pleural effusion is largely independent of the amount of ascites. The connection between the pelvic tumor and ascites is confirmed by the rapid resolution of abdominal and pleural fluid after removal of the tumor. CA125 antigen is a glycoprotein with a high molecular weight and is recognized by a monoclonal antibody (OC-125). It is expressed in the amnion and embryonic coelomic epithelium [11]. The antigen can also appear in many adult tissues such as the epithelium of the fallopian tubes, endometrium, endocervix, and ovaries [12]. In addition, it is found in mesothelial cells of the pleura, pericardium and peritoneum. Therefore, some normal body tissues can produce a certain and low level of circulatory or serum CA125. This tumor marker is found elevated during menstruation or pregnancy and in some benign conditions such as endometriosis, peritonitis or cirrhosis, particularly with ascites [13, 14]. It is also increased in vascular invasion, tissue destruction and inflammation associated with malignant disease. In a series by O'Connell et al. [15], the predictive value of a CA125 level greater than 35 U/ml was 60% for ovarian cancer and 84% for some type of malignancy. The authors also reported three patients with ovarian fibroma and elevated serum CA125 levels (above 35 U/ml) in their series. No details were given whether these patients also had Meigs’ syndrome. The coincidence of Meigs’ syndrome with elevation of serum CA125 levels has been described in the published literature in only 28 cases (table 1). The histological types reported have been fibroma (15 cases), cellular fibroma (4 cases), thecoma (4 cases), fibroma thecoma (3 cases), granulosa cell tumor (1 case), and benign Brenner tumor (1 case). Serum CA125 levels above 1,000 U/ml are exceptional, and only 6 cases with this feature have been reported previous to the present study.
Table 1

Summary of reported cases of Meigs' syndrome with elevated serum CA125 level

AuthorYearNo. of casesAgeHistopathologyCA125 U/ml
Jones and Surwit [16]1989170Fibroma/thecoma226
Hoffman [17]1989139Thecoma498
Martin et al. [18]19901NRGranulosa cell tumor307
Walker et al. [19]1990252, 67Cellular fibroma>5,000, 104
Le Bouedec et al. [20]1992266, 76Fibroma/thecoma645, 286
Williams et al. [21]1992174Luteinized thecoma329
Lin et al. [22]1992274, 72Fibroma2,120, 7,000
Turan et al. [23]1993163Thecoma744
Siddiqui and Toub [24]1995173Cellular fibroma1,780
Timmerman et al. [25]1995271, 73Fibroma484.5, 42.3
Abad et al. [5]1997151Cellular fibroma577
Chan et al. [6]2000113Fibroma970
Patsner [26]2000662, 57, 52, 60, 72, 58Fibroma185, 850, 520, 64, 1,200, 80
Buttin et al. [27]2001167Brenner tumor759
López et al. [28]2002278, 68Fibroma498, 265
Vieira et al. [29]2003165Thecoma319
Móran-Mendoza et al. [30]2004146Fibroma1,808
Current report2007156Fibroma1,064
The immunohistochemical study for CA125 suggested that serum elevation of CA125 antigen in patients with Meigs’ syndrome is caused by mesothelial expression of CA125 rather than by fibroma [22, 25]. The precise mechanism remains unclear, but a biomedical factor, mechanical irritation from a large tumor, or an increase in intraperitoneal pressure from a large volume of ascites might be primary factors in this process. The association of massive abdominal ascites, pleural effusion, and a large pelvic mass with an elevated serum CA125 level portends a poor prognosis. However, it is paramount to remember that this combination of findings does not always predict an ominous diagnosis. This case illustrates the importance of appropriate surgery to obtain histopathological confirmation of Meigs’ syndrome, as a small percentage of patients will have a benign etiology even in the presence of an elevated serum CA125 level.
  28 in total

Review 1.  Meigs' syndrome with elevated CA125: case report and review of the literature.

Authors:  A Abad; E Cazorla; F Ruiz; I Aznar; E Asins; J Llixiona
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1999-01       Impact factor: 2.435

2.  A large abdominal mass in a young girl.

Authors:  C Y Chan; S M Chan; L Liauw
Journal:  Br J Radiol       Date:  2000-08       Impact factor: 3.039

3.  Fibroma of the ovary with ascites and hydrothorax; Meigs' syndrome.

Authors:  J V MEIGS
Journal:  Am J Obstet Gynecol       Date:  1954-05       Impact factor: 8.661

Review 4.  Uterine leiomyoma associated with ascites and hydrothorax.

Authors:  S Terada; N Suzuki; K Uchide; K Akasofu
Journal:  Gynecol Obstet Invest       Date:  1992       Impact factor: 2.031

5.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

6.  Cellular fibroma masquerading as ovarian carcinoma.

Authors:  J L Walker; A Manetta; R S Mannel; S Y Liao
Journal:  Obstet Gynecol       Date:  1990-09       Impact factor: 7.661

Review 7.  Meigs' syndrome with elevated serum CA 125 levels: two case reports and review of the literature.

Authors:  D Timmerman; P Moerman; I Vergote
Journal:  Gynecol Oncol       Date:  1995-12       Impact factor: 5.482

8.  Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125.

Authors:  S E Kabawat; R C Bast; A K Bhan; W R Welch; R C Knapp; R B Colvin
Journal:  Int J Gynecol Pathol       Date:  1983       Impact factor: 2.762

9.  Cellular fibroma of the ovary with Meigs' syndrome and elevated CA-125. A case report.

Authors:  M Siddiqui; D B Toub
Journal:  J Reprod Med       Date:  1995-11       Impact factor: 0.142

Review 10.  The CA 125 tumour-associated antigen: a review of the literature.

Authors:  I Jacobs; R C Bast
Journal:  Hum Reprod       Date:  1989-01       Impact factor: 6.918

View more
  9 in total

1.  Postmenopausal Meigs' Syndrome in Elevated CA-125: A Case Report.

Authors:  Jung-Woo Park; Jong Woon Bae
Journal:  J Menopausal Med       Date:  2015-04-27

2.  A Case of Meigs' Syndrome: The (18)F-FDG PET/CT Findings.

Authors:  Eun Seong Lee; Tae-Sung Kim; Chong Woo Yoo; Sang-Soo Seo; Seok-Ki Kim
Journal:  Nucl Med Mol Imaging       Date:  2011-07-15

3.  Meigs' syndrome with elevated serum CA125 in a case of ovarian fibroma /thecoma.

Authors:  Shahla Yazdani; Abolhasan Alijanpoor; Majid Sharbatdaran; Zinatossadat Bouzari; Mohammad Abedisamakoosh; Faranak Lakaieandi; Mehdi Mohammadpour
Journal:  Caspian J Intern Med       Date:  2014

4.  A case of Meigs' syndrome with preceding pericardial effusion in advance of pleural effusion.

Authors:  Kenichi Okuda; Satoshi Noguchi; Osamu Narumoto; Masako Ikemura; Yasuhiro Yamauchi; Goh Tanaka; Daiya Takai; Masashi Fukayama; Takahide Nagase
Journal:  BMC Pulm Med       Date:  2016-05-10       Impact factor: 3.317

5.  Case of pseudo-Meigs' syndrome caused by gastric cancer-related metastatic ovarian tumor with prolonged survival.

Authors:  Masaru Okamoto; Kazunori Maeda; Atsushi Yanagitani; Kiwamu Tanaka
Journal:  World J Gastrointest Oncol       Date:  2016-11-15

6.  Meigs' Versus Pseudo-Meigs' Syndrome: A Case of Pleural Effusion, Ascites, and Ovarian Mass.

Authors:  Paul Nguyen; Omid Yazdanpanah; Brianna Schumaker
Journal:  Cureus       Date:  2020-08-12

7.  Pseudo-Meigs' Syndrome in Tunisian H Syndrome Female Patient: First Case Reported.

Authors:  Yosra Zaimi; Myriam Ayari; Asma Mensi; Linda Bel Hadj Kacem; Leila Achouri; Meriem Bouzrara; Yosra Said; Leila Mouelhi; Radhouane Debbeche
Journal:  Appl Clin Genet       Date:  2021-04-15

8.  Meigs' syndrome with elevated CA-125 and HE-4: a case of luteinized fibrothecoma.

Authors:  Jaroslaw Danilos; Wojciech Michał Kwaśniewski; Diana Mazurek; Wieslawa Bednarek; Jan Kotarski
Journal:  Prz Menopauzalny       Date:  2015-06-22

9.  Ovarian fibroma/fibrothecoma with elevated serum CA125 level: A cohort of 66 cases.

Authors:  Yuanming Shen; Yun Liang; Xiaodong Cheng; Weiguo Lu; Xing Xie; Xiaoyun Wan
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.